Share Twitter LinkedIn Facebook Email Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, explains how novel combination treatment options and sequencing strategies are used to manage relapsed/refractory multiple myeloma.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read